Menu
← Oncology Approval Tracker
FDA DECISION ·
Rybrevant + carboplatin + pemetrexed
amivantamab-vmjw with carboplatin and pemetrexed · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation and progression on or after an EGFR tyrosine kinase inhibitor.
LAMPGEN ANALYSIS
Why it matters
This combination adds an antibody-based option after EGFR inhibitor failure for common EGFR variants.
What research teams should watch
Distinguish the EGFR variant and progression setting from the exon 20 insertion regimen; reserve adequate infusion and observation capacity.
PRIMARY RECORDS